Recherche Fr menu ClientConnect
Recherche
Résultats
5 premiers résultats de la recherche Voir tous les résultats Recherche avancée
Recherches les plus fréquentes
Pages les plus visitées
    Référence: 20200584
    Date de publication: 2 octobre 2020

    Promoteur – Intermédiaire Financier

    COUNTERPART(S) TO BE DETERMINED

    Lieu

    Description

    The operation aims at increasing the local manufacturing capacity of active pharmaceutical ingredients (APIs) in sub-Saharan Africa (SSA).

    Objectifs

    The operation aims at increasing the local manufacturing capacity of active pharmaceutical ingredients (APIs) in sub-Saharan Africa. The ultimate objective is to improve the availability of pharmaceutical products in the region and to increase the robustness of the pharmaceutical supply chain by reducing dependency on imports.

    Secteur(s)

    • Santé - Santé humaine et action sociale

    Montant BEI envisagé (montant approximatif)

    EUR 50 million

    Coût total (montant approximatif)

    EUR 100 million

    Aspects environnementaux

    The overall environmental impact and the residual environmental risks of the operation are unknown at this stage and will be assessed at the appraisal of individual sub-operations. The Bank will require the beneficiaries to ensure that implementation of the sub-projects will be done in accordance with the Bank's environmental and social policy and standards.

    Passation des marchés

    The Bank will require that the beneficiaries ensure that the implementation of the sub-operations will be done in accordance with the Bank's Guide to Procurement.

    Statut

    Approuvé - 11/11/2020

    Clause de non-responsabilité

    Before financing approval by the Board of Directors, and before loan signature, projects are under appraisal and negotiation. The data provided on this page is therefore indicative and cannot be considered to represent official EIB policy (see also the Explanatory notes).

    Mots-clés correspondants

    Régional - Afrique Santé